Annovis Bio, Inc. entered into a securities purchase agreement with an institutional investor for issuance of 114,911 common shares at a price of $8.92 per share for aggregate gross proceeds of $1,025,006.12 on March 15, 2024. The parties anticipate that the closing will occur as soon as possible after the satisfaction of all of the conditions to closing including, without limitation, the listing of the common shares on the NYSE.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.36 USD | +22.04% | +56.26% | -55.29% |
05-10 | Annovis Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
05-09 | Annovis Bio, Inc. Announces Unblinding of the Buntanetap Phase III Data in Parkinson?s Disease | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-55.29% | 75.43M | |
+5.33% | 111B | |
+12.11% | 105B | |
-12.56% | 22.34B | |
-3.70% | 21.93B | |
-6.03% | 18.59B | |
-35.21% | 18.12B | |
-10.86% | 16.96B | |
+5.10% | 13.7B | |
+37.57% | 12.45B |
- Stock Market
- Equities
- ANVS Stock
- News Annovis Bio, Inc.
- Annovis Bio, Inc. announced that it expects to receive $1.025006 million in funding